


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED

領航醫藥及生物科技有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock Code: 399)

RETIREMENT OF AUDITOR; AND WITHDRAWAL OF RESOLUTION NO. 3 AT THE ANNUAL GENERAL MEETING TO BE HELD ON THURSDAY, 29 AUGUST 2024

The announcement is made by the board (the “**Board**”) of directors (the “**Director(s)**”) of Innovative Pharmaceutical Biotech Limited (the “**Company**”) pursuant to Rule 13.51(4) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

RETIREMENT OF AUDITOR

The Board announces that the Board and the audit committee of the Company have received a letter dated 14 August 2024 (the “**Letter**”) from Elite Partners CPA Limited (“**Elite Partners**”) indicating that they will retire as the auditor of the Company upon expiration of its current term of office at the conclusion of the annual general meeting of the Company to be held on Thursday, 29 August 2024 at 4:00 p.m. (the “**AGM**”) and will not seek for re-appointment as auditor of the Company at the AGM.

As stated in the Letter, in their annual consideration of whether to continue to act for their audit clients, Elite Partners has taken into consideration many factors in reaching a conclusion, including but not limited to their available internal resources. After careful consideration, Elite Partners has decided not to seek for re-appointment as the auditor of the Company.

Elite Partners has confirmed that in the Letter there are no matters that need to be brought to the attention of holders of securities or creditors of the Company. The Board has also confirmed that there is no disagreement between the Company and Elite Partners, and is not aware of any matters or circumstances in respect of the retirement of auditor that need to be brought to the attention of the shareholders of the Company (the “**Shareholders**”).

The Board would like to take this opportunity to express its sincere gratitude to Elite Partners for its professional and quality services rendered to the Company during the past years.

WITHDRAWAL OF RESOLUTION NO. 3 AT THE ANNUAL GENERAL MEETING

References are made to the circular and the notice of the annual general meeting (the “**AGM Notice**”) of the Company both dated 30 July 2024 and the form of proxy (the “**Proxy Form**”) for use at the AGM.

Due to the retirement of Elite Partners as the auditor of the Company, the ordinary resolution no. 3 in respect of the re-appointment of Elite Partners as the auditor and to authorise the Board to fix its remuneration as set out in the AGM Notice and the Proxy Form will not be put forward for consideration and approval by the Shareholders at the AGM. Save as the aforesaid, all other resolutions as set out in the AGM Notice and the Proxy Form remain valid for consideration and approval by the Shareholders at the AGM. Proxy Forms lodged by the Shareholders will remain valid except that no poll will be taken and counted for ordinary resolution no. 3.

The Board will identify a suitable replacement to fill the vacancy as soon as possible following the retirement of Elite Partners. An ordinary resolution will be proposed at an extraordinary general meeting of the Company to be convened to consider and approve the proposed appointment of the new auditor of the Company. Further announcement in relation to the appointment of the Company’s new auditor will be made by the Company as and when appropriate in accordance with the Listing Rules.

By order of the Board
Innovative Pharmaceutical Biotech Limited
Tang Rong
Executive Director

Hong Kong, 14 August 2024

As at the date of this notice, the Board comprises Ms. Jiang Nian (chairman & non-executive Director), Mr. Gao Yuan Xing (executive Director), Mr. Tang Rong (executive Director), Mr. Cheng Tak Yiu (executive Director), Ms. Xiao Yan (non-executive Director), Ms. Wu Yanmin (non-executive Director), Ms. Chen Weijun (independent non-executive Director), Mr. Wang Rongliang (independent non-executive Director) and Mr. Chen Jinzhong (independent non-executive Director).